Clinical Trials at Memorial Sloan Kettering Cancer Center

As of September 2026, 455 paid clinical trials are recruiting at Memorial Sloan Kettering Cancer Center, located at 1275 YORK AVE, MEMORIAL 7, NEW YORK, NY 10065-6007, phone (212) 639-2000 in New York, New York. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 24, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

459 clinical trials at Memorial Sloan Kettering Cancer Center

·Clear filters·

Get a weekly email when new trials open in New York, NY.

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for Pancreatic Acinar Cell Carcinoma

Sites in New York, Mineola +256 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04858334·Phase 2·Recruiting·Listed Apr 2021

Apply to this trial

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

for Metastatic Renal Cell Carcinoma

Sites in New York, Uniondale +278 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05327686·Phase 2·Recruiting·Listed Apr 2022

Apply to this trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

Sites in New York, Brooklyn +441 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting·Listed Aug 2023

Apply to this trial

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

for Clear Cell Renal Cell Carcinoma

Sites in New York, The Bronx +401 more locations

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06661720·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for Locally Advanced Cervical Adenocarcinoma

Sites in New York, Rego Park +318 more locations

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT07061977·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

Sites in New York, The Bronx +324 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

for Astrocytoma, IDH-Mutant, Grade 3

Drug: Vorasidenib

Sites in New York, Brooklyn +115 more locations

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 12+

Code: NCT07215910·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Drug: Nivolumab

Sites in New York, The Bronx +382 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 5 - 60

Code: NCT05675410·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Sites in New York, The Bronx +203 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554406·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

for Metastatic Castration-Resistant Prostate Carcinoma

Sites in New York, The Bronx +82 more locations

Sponsor: Alliance for Clinical Trials in Oncology

Sex: Male·Age: 18+

Code: NCT07200830·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Drug: Venetoclax

Sites in New York, Manhasset +211 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06317649·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for Fallopian Tube Endometrioid Adenocarcinoma

Drug: Bevacizumab

Sites in New York, Brooklyn +653 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06580314·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Drug: Venetoclax

Sites in New York, The Bronx +165 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554393·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

for Childhood Extracranial Germ Cell Tumor

Sites in New York, Brooklyn +380 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: All ages

Code: NCT03067181·Phase 3·Recruiting·Listed Mar 2017

Apply to this trial

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

for Locally Advanced Lung Non-Small Cell Carcinoma

Sites in New York, Staten Island +444 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05624996·Phase 3·Recruiting·Listed Nov 2022

Apply to this trial

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

for Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma

Sites in New York, Brooklyn +324 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06958328·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Sites in New York, Uniondale +127 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06672146·Phase 2·Recruiting·Listed Nov 2024

Apply to this trial

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

for Metastatic Head and Neck Squamous Cell Carcinoma

Sites in New York, Uniondale +187 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06589804·Phase 3·Recruiting·Listed Sep 2024

Apply to this trial

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

for Metastatic Dedifferentiated Liposarcoma

Sites in New York, The Bronx +239 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06422806·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

for Recurrent Head and Neck Squamous Cell Carcinoma

Sites in New York, The Bronx +125 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 79

Code: NCT04671667·Phase 2·Recruiting·Listed Dec 2020

Apply to this trial

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

for Metastatic Colorectal Adenocarcinoma

Sites in New York, Brooklyn +163 more locations

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05673148·Phase 2·Recruiting·Listed Jan 2023

Apply to this trial

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

for Non-Muscle Invasive Bladder Urothelial Carcinoma

Sites in New York, Uniondale +133 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06770582·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

for Lymphoplasmacytic Lymphoma

Drug: Venetoclax

Sites in New York, Uniondale +96 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04840602·Phase 2·Recruiting·Listed Apr 2021

Apply to this trial

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

for Castration-Sensitive Prostate Carcinoma

Drug: Apalutamide

Sites in New York, Uniondale +203 more locations

Sponsor: Alliance for Clinical Trials in Oncology

Sex: Male·Age: 18+

Code: NCT06931340·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

Sites in New York, Rego Park +479 more locations

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting·Listed Jan 2020

Apply to this trial

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

for Central Nervous System Nongerminomatous Germ Cell Tumor

Sites in New York, Brooklyn +140 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: 3 - 29

Code: NCT04684368·Phase 2·Recruiting·Listed Dec 2020

Apply to this trial

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

for Acute Myeloid Leukemia

Sites in New York, Brooklyn +170 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: 6 Months - 21

Code: NCT04293562·Phase 3·Recruiting·Listed Mar 2020

Apply to this trial

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

for Locally Advanced Adrenal Cortical Carcinoma

Drug: Cabozantinib

Sites in New York, Uniondale +79 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 12+

Code: NCT06900595·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

for Muscle Invasive Bladder Urothelial Carcinoma

Sites in New York, Uniondale +206 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT07097142·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

for B Acute Lymphoblastic Leukemia

Sites in New York, The Bronx +140 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 366 Days - 46

Code: NCT06124157·Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

for Metastatic Salivary Gland Carcinoma

Sites in New York, Uniondale +140 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05408845·Phase 2·Recruiting·Listed Jun 2022

Apply to this trial

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

for Acute Leukemia of Ambiguous Lineage

Drug: Venetoclax

Sites in New York, The Bronx +111 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 365 Days

Code: NCT06317662·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

for Down Syndrome

Drug: Nivolumab

Sites in New York, Brooklyn +150 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 1 - 30

Code: NCT04546399·Phase 2·Recruiting·Listed Sep 2020

Apply to this trial

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

for Recurrent Langerhans Cell Histiocytosis

Sites in New York, Brooklyn +101 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 180 Days - 22

Code: NCT05828069·Phase 2·Recruiting·Listed Apr 2023

Apply to this trial

The HOPE Biobank Resource (BMT CTN 2402 HOPE)

for Aplastic Anemias

Sites in New York +13 more locations

Sponsor: Medical College of Wisconsin

Sex: All·Age: All ages·Accepts healthy volunteers

Code: NCT07227155·Recruiting·Listed Nov 2025

Apply to this trial

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

for Malignant Glioma

Drug: Selinexor

Sites in New York, The Bronx +104 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 12 Months - 21

Code: NCT05099003·Phase 1, Phase 2·Recruiting·Listed Oct 2021

Apply to this trial

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

for B Acute Lymphoblastic Leukemia

Sites in New York, Brooklyn +185 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 25

Code: NCT03959085·Phase 3·Recruiting·Listed May 2019

Apply to this trial

A Study of a Decision Tool for People Considering Breast Reconstruction Surgery

for Breast Cancer

Sites in New York, Rockville Centre +7 more locations

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 18+

Code: NCT07335354·Recruiting·Listed Jan 2026

Apply to this trial

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

for Low Grade Astrocytoma

Drug: Selumetinib

Sites in New York, New Hyde Park +115 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 2 - 21

Code: NCT04166409·Phase 3·Recruiting·Listed Nov 2019

Apply to this trial

DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer

for Solid Tumor

Sites in New York, Rockville Centre +5 more locations

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 21 - 100·Accepts healthy volunteers

Code: NCT07225088·Recruiting·Listed Nov 2025

Apply to this trial